Treatment of EB virus positive diffuse large B cell lymphoma

VernacularTitle:EB病毒阳性弥漫大B细胞淋巴瘤的治疗
Author: Yiwei GUO ¹ ; Aichun LIU
Author Information

1. 哈尔滨医科大学附属肿瘤医院血液淋巴内科　150081
Keywords: Herpesvirus 4, human; Lymphoma, large B-cell, diffuse; Antibodies, monoclonal; Immunotherapy
From: Journal of International Oncology 2021;48(7):385-388
CountryChina
Language:Chinese
Abstract: Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma (DLBCL) is a rare type of B cell lymphoma associated with chronic EBV infection. The main subtype is activated B cell-like and it′s invasive. The response to combined chemotherapy is worse than that of EBV negative patients, and the prognosis is poor. As the researches on pathogenesis and biological characteristics of EBV positive DLBCL deepen, new therapeutic strategies are emerging, such as antiviral therapy, monoclonal antibody, inhibitors of signaling pathway and immunotherapy including cellular immunotherapy and immune checkpoint inhibitor. These new therapeutic strategies can improve the efficacy and reduce the occurrence of adverse reactions.